A Study of DT2216 in Relapsed/Refractory Malignancies
Status:
Recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
A Phase 1, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety,
Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein
Targeted Degradation Compound, in Subjects with Relapsed or Refractory Malignancies